



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:  
Lu et al.

Serial No: 09/499,526

Filed: February 10, 2000

For: Methods and Reagents for Promoting  
Maturation of Pancreatic Tissue.

Attorney Docket No. CIBT-P01-058

Art Unit: 1647

Examiner: R. DeBerry

1647  
#32F/RW  
03/28/03

For  
purposes  
only

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date indicated below:

March 17, 2003  
Date of Signature  
and of Mail Deposit

Brent LaBarge

RECEIVED

Commissioner for Patents  
Washington, D.C. 20231

MAR 26 2003

TECH CENTER 1600/2900

**REPLY UNDER 37 CFR 1.111**

Sir:

This amendment is being filed in reply to the outstanding Office Action, mailed December 17, 2002, in connection with the above application. Please enter the following amendments:

In the specification:

OO Please replace the fifth complete paragraph on page 21 with the following:

F PYY is the predominant hormone of the pancreatic polypeptide family in developing mouse and rat pancreas. It is a member of the PP family of proteins, which also includes neuropeptide Y (NPY) and pancreatic polypeptide (PP). The sequence for human PYY is given by YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID No: 3).

01/31/2005 DWILLIA4 00000002 181945 09499526

01 FC:1201 252.00 DA

FEE VALUE	
ACCOUNTABILITY	
DEPOSIT ACCOUNT NO.	
18	1945
FEE VALUE	
CODE	FURNISHED
1201	240 <i>w</i>
(3)	

(3)

5. Applicants additionally note that the specification has been amended to correct an obvious error in referring to an amino acid sequence. The specification previously identified the amino acid sequence presented on page 21 as SEQ ID NO: 1, however the sequence listing filed with the application refers to a nucleic acid sequence as SEQ ID NO: 1. One of skill in the art would readily appreciate that the reference to the amino acid sequence presented on page 21 as SEQ ID NO:1 was a clerical error and this sequence must instead be referred to using a different sequence identifier. Additionally, Applicants enclosed herewith an amended sequence listing which appropriately refers to SEQ ID NO: 3.

### CONCLUSION

In view of the foregoing amendments and remarks, Applicants submit that the pending claims are in condition for allowance. Early and favorable reconsideration is respectfully solicited. The Examiner may address any questions raised by this submission to the undersigned at 617-951-7000. Should an extension of time be required, Applicants hereby petition for same and request that the extension fee and any other fee required for timely consideration of this submission be charged to Deposit Account No. 18-1945.

Respectfully Submitted

Matthew P. Vincent  
Reg. No. 36,709

Date: March 17, 2003

Customer No: 28120  
Docketing Specialist  
Ropes & Gray  
One International Place  
Boston, MA 02110  
Phone: 617-951-7000  
Fax: 617-951-7050